(NASDAQ: ALGS) Aligos Therapeutics's forecast annual revenue growth rate of 216.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Aligos Therapeutics's revenue in 2025 is $3,174,000.On average, 2 Wall Street analysts forecast ALGS's revenue for 2025 to be $16,239,627, with the lowest ALGS revenue forecast at $7,873,759, and the highest ALGS revenue forecast at $24,605,496. On average, 1 Wall Street analysts forecast ALGS's revenue for 2026 to be $24,605,496, with the lowest ALGS revenue forecast at $24,605,496, and the highest ALGS revenue forecast at $24,605,496.
In 2028, ALGS is forecast to generate $1,470,239,900 in revenue, with the lowest revenue forecast at $1,470,239,900 and the highest revenue forecast at $1,470,239,900.